Dose schedule optimization and the pharmacokinetic driver of neutropenia

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Patel, Mayankbhai ^a   Palani, Santhosh ^a   Chakravarty, Arijit ^a   Yang, Johnny ^a   Shyu, Wen Chyi ^a   Mettetal, Jerome T ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ANTINEOPLASTIC AGENT; ETOPOSIDE; TAXOID; TOPOTECAN;

AREA UNDER THE CURVE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DOSE REGIMEN; IN VIVO STUDY; MALE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PHARMACOLOGICAL PARAMETERS; RAT; ANIMAL; BIOLOGICAL MODEL; CHEMICALLY INDUCED; DRUG ADMINISTRATION; HUMAN; SPRAGUE DAWLEY RAT; THEORETICAL MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; HUMANS; MALE; MODELS, BIOLOGICAL; MODELS, THEORETICAL; NEUTROPENIA; RATS, SPRAGUE-DAWLEY; TAXOIDS; TOPOTECAN;

EID: 84910020967     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109892     Document Type: Article

References (46)

1. Amadori S, Stasi R, Martelli AM, Venditti A, Meloni G, et al. (2012) Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). Br J Haematol 156: 205-212.
2. DuBois SG, Shusterman S, Reid JM, Ingle AM, Ahern CH, et al. (2012) Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Cancer Chemother Pharmacol 69: 1021-1027.
3. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, et al. (2011) A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 25: 341-347.
4. Oosterhuis B, ten Berge RJ, Sauerwein HP, Endert E, Schellekens PT, et al. (1984) Pharmacokinetic-pharmacodynamic modeling of prednisolone-induced lymphocytopenia in man. J Pharmacol Exp Ther 229: 539-546.
5. Fetterly GJ, Tamburlin JM, Straubinger RM (2001) Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model. Biopharm Drug Dispos 22: 251-261.
6. Silber JH, Fridman M, DiPaola RS, Erder MH, Pauly MV, et al. (1998) First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 16: 2392-2400.
7. Link BK, Budd GT, Scott S, Dickman E, Paul D, et al. (2001) Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer 92: 1354-1367.
8. Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, et al. (2004) A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15: 1358-1365.
9. Qi M, Li JF, Xie YT, Lu AP, Lin BY, et al. (2010) Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer. Breast Cancer Res Treat 123: 197-202.
10. Huang TC, Campbell TC (2012) Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis. Cancer Treat Rev 38: 613-617.
11. Bria E, Cuppone F, Ciccarese M, Nistico C, Facciolo F, et al. (2006) Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev 32: 583-587.
12. Socinski MA (1999) Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. Oncologist 4: 408-416.
13. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, et al. (1984) Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res 44: 5432-5438.
14. Duffull SB, Robinson BA (1997) Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 33: 161-183.
15. Arakawa A, Nishikawa H, Suzumori K, Kato N (2001) Pharmacokinetic and pharmacodynamic analysis of combined chemotherapy with carboplatin and paclitaxel for patients with ovarian cancer. Int J Clin Oncol 6: 248-252.
16. Jakobsen P, Bastholt L, Dalmark M, Pfeiffer P, Petersen D, et al. (1991) A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. Cancer Chemother Pharmacol 28: 465-469.
17. Ando M, Minami H, Ando Y, Sakai S, Shimono Y, et al. (1999) Pharmacological analysis of etoposide in elderly patients with lung cancer. Clin Cancer Res 5: 1690-1695.
18. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, et al. (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10: 520-528.
19. Testart-Paillet D, Girard P, You B, Freyer G, Pobel C, et al. (2007) Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice. Crit Rev Oncol Hematol 63: 1-11.
20. van Groeningen CJ, Pinedo HM, Heddes J, Kok RM, de Jong AP, et al. (1988) Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 48: 6956-6961.
21. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, et al. (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13: 180-190.
22. Henningsson A, Sparreboom A, Sandstrom M, Freijs A, Larsson R, et al. (2003) Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer 39: 1105-1114.
23. Huizing MT, Keung AC, Rosing H, van der Kuij V, ten Bokkel Huinink WW, et al. (1993) Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11: 2127-2135.
24. Karlsson MO, Molnar V, Bergh J, Freijs A, Larsson R (1998) A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 63: 11-25.
25. Walker LG, Eremin JM, Aloysius MM, Vassanasiri W, Walker MB, et al. (2011) Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer. BMC Cancer 11: 179.
26. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20: 4713-4721.
27. Sandstrom M, Lindman H, Nygren P, Lidbrink E, Bergh J, et al. (2005) Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol 23: 413-421.
28. Troconiz IF, Garrido MJ, Segura C, Cendros JM, Principe P, et al. (2006) Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Cancer Chemother Pharmacol 57: 727-735.
29. Latz JE, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD (2006) A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 57: 412-426.
30. Leger F, Loos WJ, Bugat R, Mathijssen RH, Goffinet M, et al. (2004) Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther 76: 567-578.
31. Zandvliet AS, Siegel-Lakhai WS, Beijnen JH, Copalu W, Etienne-Grimaldi MC, et al. (2008) PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression. Clin Pharmacol Ther 83: 829-839.
32. van Kesteren C, Zandvliet AS, Karlsson MO, Mathot RA, Punt CJ, et al. (2005) Semi-physiological model describing the hematological toxicity of the anticancer agent indisulam. Invest New Drugs 23: 225-234.
33. Brain EG, Rezai K, Lokiec F, Gutierrez M, Urien S (2008) Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: an n = 1 randomized study. Br J Clin Pharmacol 65: 607-610.
34. Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO (2006) Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res 12: 5481-5490.
35. Friberg LE, Freijs A, Sandstrom M, Karlsson MO (2000) Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. J Pharmacol Exp Ther 295: 734-740.
36. Friberg LE, Sandstrom M, Karlsson MO (2010) Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model. Invest New Drugs 28: 744-753.
37. Hansson EK, Friberg LE (2012) The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia. Cancer Chemother Pharmacol 69: 881-890.
38. Hansson EK, Wallin JE, Lindman H, Sandstrom M, Karlsson MO, et al. (2010) Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemother Pharmacol 65: 839-848.
39. Latz JE, Rusthoven JJ, Karlsson MO, Ghosh A, Johnson RD (2006) Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 57: 427-435.
40. Sandstrom M, Lindman H, Nygren P, Johansson M, Bergh J, et al. (2006) Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 58: 143-156.
41. Sandstrom M, Simonsen LE, Freijs A, Karlsson MO (1999) The pharmacokinetics of epirubicin and docetaxel in combination in rats. Cancer Chemother Pharmacol 44: 469-474.
42. Wallin JE, Friberg LE, Karlsson MO (2010) Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information. Basic Clin Pharmacol Toxicol 106: 234-242.
43. Hikichi Y, Honda K, Hikami K, Miyashita H, Kaieda I, et al. (2012) TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther 11: 700-709.
44. Miller AA, Herndon JE, Hollis DR, Ellerton J, Langleben A, et al. (1995) Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 13: 1871-1879.
45. Hande KR, Krozely MG, Greco FA, Hainsworth JD, Johnson DH (1993) Bioavailability of low-dose oral etoposide. J Clin Oncol 11: 374-377.
46. Toffoli G, Corona G, Basso B, Boiocchi M (2004) Pharmacokinetic optimisation of treatment with oral etoposide. Clin Pharmacokinet 43: 441-466.